Welcome to FMI : Your Trusted Source for 100% Authentic Supplements.

100% AUTHENTIC

FAST WORLDWIDE SHIPPING

TRUSTED BY 50K+ Customers

LIMITED STOCK

100% Authentic

Authorised Distributor

Made in USA

1- 5 day delivery

Quick Instruction Video Guide

  • Specifications

  • Lable

  • Dosage

For Future - to Make it More Content Rich 

We will be using this area.

GI MAP X 1 Test Kit

Advanced Screening for IBS, Overgrowth & Dysbiosis

Brand: Nordic Laboratories

Rs. 37,525

Price includes all duties and taxes

SKU: TK-GI-MAP

Quantity

Category: Dysbiosis/Gastrointestinal function/Infection/State of intestinal flora/Bacterial overgrowth/Irritable Bowel Syndrome (IBS)
Sample type: Stool
Sample Collection Instructions:

  • Sample collections are conducted on Tuesday and Thursday.
  • Clients must inform us 24 hrs. before to schedule the next day collection by 4pm so that we can arrange the collection accordingly.

Average processing time: 21±4 days days

Disclaimer: This test provides information to support health and wellness assessments and should not substitute for medical diagnosis, treatment, or professional healthcare advice.
Nordic Laboratories
  • Specifications

  • Lable

  • Dosage

  • INDICATIONS

  • OVERVIEW

  • PRACTICAL

  • RESEARCH

  • Digestive symptoms: Chronic diarrhoea, constipation, bloating, gas or abdominal pain.
  • Altered bowel habits: Ongoing changes in stool frequency, urgency or consistency.
  • Suspected gastrointestinal disorders: Evaluation in contexts such as irritable bowel syndrome, inflammatory bowel disease or coeliac disease.
  • Recurrent gastrointestinal symptoms: Exploration of potential bacterial contributors including Escherichia coli or Helicobacter pylori.
  • Malabsorption concerns: Unexplained weight loss, anaemia or signs of nutrient insufficiency.
  • Immune-related conditions: Investigation of gastrointestinal factors in autoimmune or inflammatory presentations.
  • Skin conditions: Eczema, acne or psoriasis where gut involvement is considered.
  • Fatigue or neurological symptoms: Brain fog, low energy or mood changes in complex clinical presentations.

Specimen

Stool sample

 

Container

  • 1x orange-capped stool vial

Patient preparation

  • Please refrain from taking aspirin for two days prior to collecting your sample.
  • Never discontinue prescription medication without first consulting your physician.

Age requirements

Can be used on all ages. However, often the microbiome of infants will appear very “dysbiotic”, as the microbiome and the infant’s immune system is very immature.

 

Available add-ons:

• Zonulin

 

Medications

We recommend continuing all prescription medications prior to testing. Please carefully document any relevant recent or current medication use. Medications that may alter the composition of the microbiome include:

  • Antibiotics -(after finishing Antibiotics, wait 4-6 weeksbefore collecting sample)
  • Immune Suppressants/ Oral steroids- will likely cause a lower Secretory IgA, Anti-gliadin, and calprotectin result (after finishing these meds, wait 4-6 weeks before collecting sample)

Gastroenterology Procedures:
Wait at least 4 weeks from colonoscopy or barium enema before beginning the test.


Supplements:
It is not necessary to discontinue most supplements before testing.  It is the provider’s discretion to recommend discontinuing supplements.  Many providers will want to understand the impact of supplements on the gut ecosystem and will want their patients to continue supplements during testing.  If a provider wants more of a “baseline” assessment using the GI-MAP, they may recommend discontinuing supplements prior to testing. There are a few categories of supplements that deserve consideration:

Non-prescription anti-microbial agents:
While we don’t require that people discontinue antibiotics or antimicrobial substances before collection their stool sample, doing the test while taking these substances can influence the test results.  If possible, we recommend discontinuing anti-microbial agents 4-6 weeks before testing.

Enzymes:
Oral enzyme use will not change the elastase-1 finding. If the enzyme contains lipase or ox bile, it may decrease the value for steatocrit.

Ox Bile/Lipase:
Ox bile/lipase intake will affect the steatocrit level but will not affect Elastase-1. If you would like to see your patient’s baseline without supplementation, discontinue at least 3 days before testing. If you would like to see how well-managed your patient is on their supplement, do not discontinue.

Probiotics:
Probiotic supplements can influence the normal and opportunistic bacteria flora. If you would like to assess your patient’s baseline microbial balance without supplementation, discontinue for ~2 weeks prior to testing. If you would like to see the influence of the current probiotic supplement, do not discontinue prior to testing.  

Biofilm disruptors:
There is no published evidence to suggest that a biofilm disruptor will improve detection of organisms. However, some clinicians choose to use a biofilm disruptor with their patients up to 14 days before testing. This is an option but not a requirement for testing.

  • Abubakar I, Irvine L, Aldus CF, et al. A systematic review of the clinical, public health and costeffectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food. Health Technol Assess. 2007;11(36):1-216.
  • Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of Eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English casecontrol Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis. 2007;26(5):311-323.
  • Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability — a new target for disease prevention and therapy. BMC gastroenterology. 2014;14:189.
  • Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infection and immunity. 2008;76(8):3360-3373.
  • Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature clinical practice. 2005;2(9):416-422.
  • Iijima Y, Asako NT, Aihara M, Hayashi K. Improvement in the detection rate of diarrhoeagenic Bacteria in human stool specimens by a rapid real-time PCR assay. Journal of medical microbiology. 2004;53(Pt 7):617-622.
  •  Kahlau P, Malecki M, Schildgen V, et al. Utility of two novel multiplexing assays for the detection of gastrointestinal pathogens - a first experience. SpringerPlus. 2013;2(1):106.
  • Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nature reviews. Immunology. 2013;13(5):321-335.
  • Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clinic proceedings. 2014;89(1):107-114.
  • Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Current opinion in gastroenterology. 2008;24(1):11-16.
  •  Rashid T, Ebringer A. Autoimmunity in Rheumatic Diseases Is Induced by Microbial Infections via Crossreactivity or Molecular Mimicry. Autoimmune diseases. 2012;2012:539282. 
  • Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. Journal of clinical microbiology. 2004;42(10):4512-4518.
  • Stecher B, Hardt WD. The role of microbiota in infectious disease.Trends in microbiology. 2008;16(3):107-114.
  •  Tiwana H, Wilson C, Walmsley RS, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatology international. 1997;17(1):11-16.
  • INDICATIONS

  • OVERVIEW

  • PRACTICAL

  • RESEARCH

  • Digestive symptoms: Chronic diarrhoea, constipation, bloating, gas or abdominal pain.
  • Altered bowel habits: Ongoing changes in stool frequency, urgency or consistency.
  • Suspected gastrointestinal disorders: Evaluation in contexts such as irritable bowel syndrome, inflammatory bowel disease or coeliac disease.
  • Recurrent gastrointestinal symptoms: Exploration of potential bacterial contributors including Escherichia coli or Helicobacter pylori.
  • Malabsorption concerns: Unexplained weight loss, anaemia or signs of nutrient insufficiency.
  • Immune-related conditions: Investigation of gastrointestinal factors in autoimmune or inflammatory presentations.
  • Skin conditions: Eczema, acne or psoriasis where gut involvement is considered.
  • Fatigue or neurological symptoms: Brain fog, low energy or mood changes in complex clinical presentations.

Specimen

Stool sample

 

Container

  • 1x orange-capped stool vial

Patient preparation

  • Please refrain from taking aspirin for two days prior to collecting your sample.
  • Never discontinue prescription medication without first consulting your physician.

Age requirements

Can be used on all ages. However, often the microbiome of infants will appear very “dysbiotic”, as the microbiome and the infant’s immune system is very immature.

 

Available add-ons:

• Zonulin

 

Medications

We recommend continuing all prescription medications prior to testing. Please carefully document any relevant recent or current medication use. Medications that may alter the composition of the microbiome include:

  • Antibiotics -(after finishing Antibiotics, wait 4-6 weeksbefore collecting sample)
  • Immune Suppressants/ Oral steroids- will likely cause a lower Secretory IgA, Anti-gliadin, and calprotectin result (after finishing these meds, wait 4-6 weeks before collecting sample)

Gastroenterology Procedures:
Wait at least 4 weeks from colonoscopy or barium enema before beginning the test.


Supplements:
It is not necessary to discontinue most supplements before testing.  It is the provider’s discretion to recommend discontinuing supplements.  Many providers will want to understand the impact of supplements on the gut ecosystem and will want their patients to continue supplements during testing.  If a provider wants more of a “baseline” assessment using the GI-MAP, they may recommend discontinuing supplements prior to testing. There are a few categories of supplements that deserve consideration:

Non-prescription anti-microbial agents:
While we don’t require that people discontinue antibiotics or antimicrobial substances before collection their stool sample, doing the test while taking these substances can influence the test results.  If possible, we recommend discontinuing anti-microbial agents 4-6 weeks before testing.

Enzymes:
Oral enzyme use will not change the elastase-1 finding. If the enzyme contains lipase or ox bile, it may decrease the value for steatocrit.

Ox Bile/Lipase:
Ox bile/lipase intake will affect the steatocrit level but will not affect Elastase-1. If you would like to see your patient’s baseline without supplementation, discontinue at least 3 days before testing. If you would like to see how well-managed your patient is on their supplement, do not discontinue.

Probiotics:
Probiotic supplements can influence the normal and opportunistic bacteria flora. If you would like to assess your patient’s baseline microbial balance without supplementation, discontinue for ~2 weeks prior to testing. If you would like to see the influence of the current probiotic supplement, do not discontinue prior to testing.  

Biofilm disruptors:
There is no published evidence to suggest that a biofilm disruptor will improve detection of organisms. However, some clinicians choose to use a biofilm disruptor with their patients up to 14 days before testing. This is an option but not a requirement for testing.

  • Abubakar I, Irvine L, Aldus CF, et al. A systematic review of the clinical, public health and costeffectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food. Health Technol Assess. 2007;11(36):1-216.
  • Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of Eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English casecontrol Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis. 2007;26(5):311-323.
  • Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability — a new target for disease prevention and therapy. BMC gastroenterology. 2014;14:189.
  • Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infection and immunity. 2008;76(8):3360-3373.
  • Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature clinical practice. 2005;2(9):416-422.
  • Iijima Y, Asako NT, Aihara M, Hayashi K. Improvement in the detection rate of diarrhoeagenic Bacteria in human stool specimens by a rapid real-time PCR assay. Journal of medical microbiology. 2004;53(Pt 7):617-622.
  •  Kahlau P, Malecki M, Schildgen V, et al. Utility of two novel multiplexing assays for the detection of gastrointestinal pathogens - a first experience. SpringerPlus. 2013;2(1):106.
  • Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nature reviews. Immunology. 2013;13(5):321-335.
  • Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clinic proceedings. 2014;89(1):107-114.
  • Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Current opinion in gastroenterology. 2008;24(1):11-16.
  •  Rashid T, Ebringer A. Autoimmunity in Rheumatic Diseases Is Induced by Microbial Infections via Crossreactivity or Molecular Mimicry. Autoimmune diseases. 2012;2012:539282. 
  • Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. Journal of clinical microbiology. 2004;42(10):4512-4518.
  • Stecher B, Hardt WD. The role of microbiota in infectious disease.Trends in microbiology. 2008;16(3):107-114.
  •  Tiwana H, Wilson C, Walmsley RS, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatology international. 1997;17(1):11-16.

Frequently Asked Questions (FAQ's)

Are there any restrictions on taking medications or undergoing medical procedures prior to the test?

Yes. You must refrain from taking aspirin for two days before collecting your sample. If you have had a gastroenterology procedure such as a colonoscopy or barium enema, you must wait at least 4 weeks before starting the test. Furthermore, if you have finished antibiotics, immune suppressants, or oral steroids, you should wait 4 to 6 weeks before collecting your sample. Never discontinue prescription medications without consulting your physician.

Do I need to stop taking my everyday supplements before doing this test?

It is generally not required to discontinue most supplements, but it depends on what your provider wants to measure. If you want to see a clean "baseline" of your gut, you should stop probiotics for about 2 weeks, non-prescription anti-microbials for 4–6 weeks, and ox bile/lipase at least 3 days before testing. If you want to see how well-managed your gut is while on your current supplement routine, you do not need to discontinue them.

How long does it take to get the results back for the GI-MAP test?

The average processing time to receive the test results is 21 ± 4 days.

Can this test be used for young infants?

The test can technically be used on individuals of all ages. However, the product details note that the microbiome of infants will often appear very “dysbiotic” simply because an infant’s microbiome and immune system are still very immature.

Retro Volition Product Demo x 450 gm

Rs. 57,500
Powered by Omni Themes